The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.b

Pneumonitis (interstitial lung disease/ILD)

Publications

Rudzianskiene M, Griniute R, Juozaityte E, Inciura A, Rudzianskas V, Emilia Kiavialaitis G

Corticosteroid-responsive pulmonary toxicity associated with fludarabine monophosphate: a case report.

Turkish journal of haematology : official journal of Turkish Society of Haematology. 2012;29(4):392-6

Helman DL Jr, Byrd JC, Ales NC, Shorr AF

Fludarabine-related pulmonary toxicity: a distinct clinical entity in chronic lymphoproliferative syndromes.

Chest. 2002;122(3):785-90

Stoica GS, Greenberg HE, Rossoff LJ

Corticosteroid responsive fludarabine pulmonary toxicity.

American journal of clinical oncology. 2002;25(4):340-1

Levin M, Aziz M, Opitz L

Steroid-responsive interstitial pneumonitis after fludarabine therapy.

Chest. 1997;111(5):1472-3